CORONA Remedies credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026
143143
98.798.7
0.19×0.19×
0.13×0.13×
0.49×0.49×
0.30×0.34×
36.67×36.67×
15.1%16.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,217.40

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,562 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt142.9142.9
Net Debt98.798.7
Total Debt/Equity0.190.19
Net Debt/Equity0.130.13
Total Debt/EBITDA0.490.49
Net Debt/EBITDA0.340.30
Interest Coverage (EBIT/Interest)36.6736.67
Total Debt/Total Capital %16.0615.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.